Sign In
Buy NKTR
$59.23
+0.670 (+1.14%)
At Close: Jun 03, 2026
Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates
11:00pm, Thursday, 06'th Aug 2020
Nektar (NKTR) delivered earnings and revenue surprises of 34.78% and 113.84%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Nektar Therapeutics Reports Second Quarter 2020 Financial Results
08:15pm, Thursday, 06'th Aug 2020
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2020.
The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO
12:00am, Thursday, 06'th Aug 2020
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 5)
ABIOMED, Inc. (NASDAQ: ABMD)
Aerpio Pharmaceuticals Inc (NASDAQ: ARPO) (announced a U.S. government grant for a...
If You Had Bought Nektar Therapeutics (NASDAQ:NKTR) Stock Five Years Ago, You Could Pocket A 106% Gain Today
03:15pm, Wednesday, 05'th Aug 2020
When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, you can make far...
Nektar Therapeutics (NASDAQ:NKTR) Shares Acquired by Nisa Investment Advisors LLC
08:30am, Wednesday, 05'th Aug 2020
Nisa Investment Advisors LLC lifted its holdings in shares of Nektar Therapeutics (NASDAQ:NKTR) by 84.8% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
12:00am, Sunday, 02'nd Aug 2020
Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts.
COVID-19 news flow continued to pour in,...
Earnings Preview: Nektar Therapeutics (NKTR) Q2 Earnings Expected to Decline
04:33pm, Thursday, 30'th Jul 2020
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2020 on Thursday, August 6, 2020, after the close of U.S.-based financial markets. Howard Robin, President
Candriam Luxembourg S.C.A. Sells 70,071 Shares of Nektar Therapeutics (NASDAQ:NKTR)
06:54am, Monday, 27'th Jul 2020
Candriam Luxembourg S.C.A. reduced its position in Nektar Therapeutics (NASDAQ:NKTR) by 18.2% during the second quarter, according to the company in its most recent 13F filing with the Securities & Ex
IPO Update: Pandion Therapeutics Seeks $94 Million IPO
02:48pm, Tuesday, 14'th Jul 2020
Pandion Therapeutics has filed proposed terms for its IPO. The company is developing treatments for gastrointestinal and liver diseases.
Die Mücke tötet durchschnittlich 725'000 Menschen pro Jahr - Blick
10:42am, Saturday, 04'th Jul 2020
Sie stoppte Hannibal vor Rom, vernichtete die indigene Bevölkerung Amerikas, schaffte aber auch die Sklaverei ab: Kein Tier hat die Menschheitsgeschichte mehr geprägt als die Mücke wie ein neues B
Medicenna Company Update And Upcoming Catalysts
12:38pm, Wednesday, 01'st Jul 2020
Medicenna's IL-2 engineered Superkine MDNA11 recently replaced MDNA19 as Medicenna's potential best-in-class IL2 candidate to move forward. IND to be filed and
Analyzing Creative Realities (CRDF) and Its Peers
02:40am, Tuesday, 30'th Jun 2020
Creative Realities (NASDAQ: CRDF) is one of 141 public companies in the “Biological products, except diagnostic” industry, but how does it compare to its competitors? We will compare Creative Real
Global Oncology Drugs Market Outlook 2020-2030: COVID-19 Impact and Recovery Assessment - ResearchAndMarkets.com
12:00am, Tuesday, 30'th Jun 2020
The
Nektar Therapeutics (NASDAQ: NKTR) Q1 2020 Earnings Call Transcript | AlphaStreet
03:08pm, Friday, 26'th Jun 2020
Final earnings conference call transcript of Nektar Therapeutics - NKTR stock
